Carole Ben-Maimon (Larimar)
Deaths of monkeys spur clinical hold for rare disease biotech's lead and only drug — and a $95M cash infusion goes out the window
In the world of small public biotechs, one mishap can be punishing.
Just ask Larimar Therapeutics, which disclosed late Tuesday that the FDA has placed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
